PetVivo (PETV) 10-Q 19 Aug 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Jun. 30, 2019shares
Document And Entity Information
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	22,074,667
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Current Assets
Cash and cash equivalents	$ 65,641	$ 6,460
Accounts receivable	450
Inventory	12,495	12,495
Employee advance	2,500	2,500
Investments - equity securities receivable	1,500
Prepaid expenses	45,484	34,327
Total Current Assets	128,070	55,782
Property and Equipment:
Property and equipment	148,798	149,802
Less: accumulated depreciation	(118,430)	(112,453)
Total Property and Equipment	30,368	37,349
Other Assets:
Trademark and patents-net	472,468	589,817
Operating lease right-of-use	99,199
Security deposit	8,201	8,201
Total Other Assets	579,868	598,018
Total Assets	738,306	691,149
Current Liabilities
Accounts payable and accrued expenses	849,668	854,990
Accrued expenses - related party	578,098	576,393
Operating lease liability	22,652
Notes payable and accrued interest	10,303	18,831
Notes payable and accrued interest - related party	75,941	85,752
Total Current Liabilities	1,536,662	1,535,966
Other Liabilities:
Convertible notes payable	280,000
Operating lease liability	76,547
Total Other Liabilities	356,547
Total Liabilities	1,893,209	1,535,966
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, par value $0.001, 20,000,000 shares authorized 0 and 0 shares outstanding at June 30, 2019 and March 31, 2019, respectively
Common stock, par value $0.001, 250,000,000 shares authorized 22,074,667 and 22,074,667 shares outstanding at June 30, 2019 and March 31, 2019, respectively	22,074	22,074
Common stock to be issued	120,000	86,333
Additional Paid-In Capital	51,709,822	51,552,688
Accumulated Deficit	(53,006,799)	(52,505,912)
Total Stockholders' Deficit	(1,154,903)	(844,817)
Total Liabilities and Stockholders' Deficit	$ 738,306	$ 691,149

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	22,074,667	22,074,667
Common stock, shares outstanding	22,074,667	22,074,667

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues
Cost of Sales
Gross Profit
Operating Expenses:
Sales and Marketing	2,796
General and Administrative:
Depreciation and Amortization	144,090	161,119
Other General and Administrative	346,835	1,935,969
Total General and Administration	490,925	2,097,088
Total Operating Expenses	493,721	2,097,088
Operating Loss	(493,721)	(2,097,088)
Other Income (Expense)
Gain on Sale of Asset	450
Interest Expense	(7,616)	(2,497)
Total Other Expense	(7,166)	(2,497)
Net Loss before taxes	(500,887)	(2,099,585)
Income Tax Provision
Net Loss	$ (500,887)	$ (2,099,585)
Net Loss Per Share: Basic and Diluted	$ (0.02)	$ (0.11)
Weighted Average Common Shares Outstanding: Basic and Diluted	22,074,667	19,584,396

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Common Stock to be Issued [Member]	Total
Balance at Mar. 31, 2018	$ 18,279	$ 47,257,557	$ (47,748,154)	$ 608,966	$ 136,648
Balance, shares at Mar. 31, 2018	18,279,075
Common stock issued	$ 1,005	607,961		(608,966)
Common stock issued, shares	1,005,287
Common stock issued to replace shares to officer	$ 804	1,445,289			1,446,093
Common stock issued to replace shares to officer, shares	803,385
Stock-based compensation		279,313		2,700	282,013
Stock granted for debt conversion	$ 95	$ 95,367			$ 95,462
Stock granted for debt conversion, shares	95,462
Common stock sold				93,892	93,892
Net loss			$ (2,099,585)		$ (2,099,585)
Balance at Jun. 30, 2018	$ 20,183	49,685,487	(49,847,739)	96,592	(45,477)
Balance, shares at Jun. 30, 2018	20,183,209
Balance at Mar. 31, 2019	$ 22,074	51,552,688	(52,505,912)	86,333	(844,817)
Balance, shares at Mar. 31, 2019	22,074,667
Stock-based compensation		157,134		33,667	190,801
Net loss			(500,887)		(500,887)
Balance at Jun. 30, 2019	$ 22,074	$ 51,709,822	$ (53,006,799)	$ 120,000	$ (1,154,903)
Balance, shares at Jun. 30, 2019	22,074,667

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (500,887)	$ (2,099,585)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock-based compensation	190,801	1,823,567
Depreciation and amortization	144,090	161,119
Interest accrued on Convertible Notes Payable	5,362
Interest accrued on Notes Payable - related party	1,590
Interest accrued on Notes Payable	471
Gain on sale of asset	(450)
Changes in Operating Assets and Liabilities
Increase in inventory		(78,730)
Increase in prepaid expenses and employee advances	(11,157)	(6,547)
Decrease in advances and receivables		163
Decrease in accounts payable and accrued expense	(5,322)	(49,774)
Increase of accrued expenses - related party	1,705	5,182
Net Cash Used In Operating Activities	(173,797)	(244,605)
CASH FLOWS FROM INVESTING ACTIVITIES
Decrease in security deposit		1,999
Increase in investments - equity securities receivable	(1,500)
Purchase of equipment		(23,181)
Increase in patents and trademarks	(19,760)	(32,612)
Net Cash Used in Investing Activities	(21,260)	(53,794)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock sale		93,893
Proceeds from convertible notes	280,000
Repayments of convertible notes	(5,362)
Repayments of notes payable	(9,000)
Repayments of notes payable - related party	(11,400)
Decrease in notes payable and accrued interest		(503)
Net Cash Provided by Financing Activities	254,238	93,390
Net Increase (Decrease) in Cash	59,181	(205,009)
Cash at Beginning of Period	6,460	237,335
Cash at End of Period	65,641	32,326
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Period For: Interest	$ 7,676	$ 2,497

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of production, marketing and distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at June 30, 2019 and for the three months ended June 30, 2019 and 2018 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended March 31, 2020 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2019, included in our annual report on Form 10-K filed with the SEC. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At June 30, 2019, the Company had $65,641 in cash and no cash equivalents. At March 31, 2019, the Company had $6,460 in cash and no cash equivalents. (F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At June 30, 2019, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash. (G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. (I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 4,370,736 warrants outstanding as of June 30, 2019 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.48/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company has 4,243,236 warrants outstanding as of March 31, 2019 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.50/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share detailed in Note 14. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive. (J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. (K) Research and Development The Company expenses research and development costs as incurred. (L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2019 and March 31, 2019, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at June 30, 2019, see Note 5 to the financial statements included in this Form 10-Q. The Company had no assets and liabilities measured at fair value on a recurring basis at March 31, 2019. (M) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 2 years. However, management reserves the right to review and adjust this as appropriate. (P) Recently Issued and Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASU 2016-02 on April 1, 2019. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (Subtopic 825) to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The amendments in this Update affect all entities that hold financial assets or owe financial liabilities. The amendments are meant to improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income since this Update requires equity securities to be measured at fair value with changes in the fair value recognized through net income. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-01 on April 1, 2018. In August 2016, the FASB issued ASU No. 2016-15 Statement of Cashflows (Topic 230) to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. This Update addresses eight specific cash flow issues and their presentations in the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2016-15 on April 1, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Going Concern

Going Concern	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $500,887 for the three-month period ended June 30, 2019 and had net cash used in operating activities of $173,797 for the same period. Additionally, the Company has an accumulated deficit of $53,006,799 and working capital deficit of $1,408,592 at June 30, 2019. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months after the date of issuance on these financial statements. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to achieve a level of profitability and/or to obtain adequate financing through the issuance of debt or equity in order to finance its operations. Management intends to raise additional funds either through a private placement or public offering of its equity securities. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Inventory

Inventory	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventory	NOTE 3 – INVENTORY On November 1, 2018 the Company and its independent contract quality control organization discovered a possible contamination in vials produced from lots #1, #2 and #3 of three separate lots that were included in inventory. No vials derived from lots #2 and #3 have been distributed to customers. No evidence of contamination of vials distributed from lot #1 has been identified to date. No adverse events arising from use of product from lot #1 have been reported to the Company. The identified lots and vials were produced by the Company’s former third-party contract manufacturer. On November 5, 2018 we issued a formal Notice of Product Quarantine and Product Monitoring Period whereby we asked for any unused vials to be quarantined while the Company’s scientific team and third-party contract testing organization coordinated and performed testing on lots #1 and #2, and analyzed the events leading to this situation. As of March 31, 2019, a reserve of approximately $67,000 in inventory has been taken in relation to this event due to the lack of sales when product was available leading to substantial doubt in the Company’s ability to obtain material sales if the product gets cleared for release, the amount of time it has taken the Company to analyze whether release of product is appropriate leaving little time before the product’s expiration date arrives, and the level of uncertainty as it relates to how pervasive any unidentified contamination may be in existing units of Kush in lots #1 and #2. Approximately $20,000 in inventory has been written off in relation to additional third-party product testing of lot #1 and approximately $5,000 in relation to lot #2. We also wrote-down the entirety of lot #3 in the amount of $5,166, which was a work-in-process when contamination was discovered. Total Inventory is broken out as follows: June 30, 2019 March 31, 2019 Finished Goods $ 67,310 $ 77,936 Reserve for Obsolete Inventory (67,310 ) (77,936 ) Work in Process -0- -0- Manufacturing Supplies 3,127 3,127 Raw Materials 9,368 9,368 Total Inventory $ 12,495 $ 12,495

Lease and Commitments

Lease and Commitments	3 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 4 – LEASE AND COMMITMENTS Rent expense for the three months ended June 30, 2019 and 2018 was $14,546 and $14,607, respectively. On July 2 nd The Company entered into an eighty-four-month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The base rent is $2,078 per month and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2019: Year Ended March 31, 2020 $ 18,702 2021 24,936 2022 24,936 2023 24,936 2024 10,390 $ 103,900 In compliance with ASC 842 the Company adopted new guidance in relation to lease accounting on April 1, 2019 whereby we recognized operating lease right-to-use assets and corresponding and equal operating lease liabilities. The planned future base rent lease payments total $103,900, which has been discounted to $101,269 using a the 52-week treasury bill coupon equivalent discount rate of 2.18% and a present value model. The Company only had one operating lease so that the weighted average remaining lease term and weighted average discount rate are approximately 4.2 years and 2.18%, respectively. June 30, 2019 Present value of future base rent lease payments $ 101,269 Base rent payments included in prepaid expenses (2,070 ) Present value of future base rent lease payments – net 99,199 As of June 30, 2019, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: June 30, 2019 Operating lease right-of-use current asset $ - Operating lease right-of-use other asset 99,199 Total operating lease assets 99,199 Operating lease current liability 22,652 Operating lease other liability 76,547 Total operating lease liabilities $ 99,199 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until the lease’s termination in 2017, the Company owes approximately $330,000 to the lessor as of the balance sheet date; this amount is included in accounts payable.

Investments - Equity Securities

Investments - Equity Securities	3 Months Ended
	Jun. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments - Equity Securities	NOTE 5 – INVESTMENTS – EQUITY SECURITIES On June 28, 2019, the Company entered into a purchase agreement with a third-party to purchase 1,500,000 shares of Emerald Organic Products, Inc. (OTC Pink: “EMOR”) common stock for consideration of $1,500. The Company applied guidance from ASU No. 2016-01 Financial Instruments – Overall – Recognition and Measurement of Financial Assets and Financial Liabilities and ASC 820 to arrive at a fair value at June 30, 2019 of $1,500. The Company took into account many factors when determining the stock’s fair value including, but not limited to, the nature and duration of the restriction on the stock, the extent to which potential buyers would be limited by the restriction, and qualitative and quantitative factors specific to both the instrument and the issuer.

Property and Equipment

Property and Equipment	3 Months Ended
	Jun. 30, 2019
Property and Equipment:
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT The components of property and equipment were as follows: June 30, 2019 March 31, 2019 Leasehold improvements $ 4,602 $ 4,602 Furniture and office equipment 10,130 10,130 Production equipment 108,882 108,882 R&D equipment 25,184 26,188 Total, at cost 148,798 149,802 Accumulated depreciation (118,430 ) (112,453 ) Total, net $ 30,368 $ 37,349 During the three months ended June 30, 2019 and 2018, depreciation expense was $6,981 and $1,652, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 7 – INTANGIBLE ASSETS The components of intangible assets, all of which are finite-lived, were as follows: June 30, 2019 March 31, 2019 Patents $ 3,838,865 $ 3,820,374 Trademarks 24,098 22,829 Total, at cost 3,862,963 3,843,203 Accumulated Amortization (3,390,495 ) (3,253,386 ) Total, net $ 472,468 $ 589,817 During the three-month periods ended June 30, 2019 and 2018, amortization expense was $137,109 and $159,467, respectively.

Convertible Notes and Notes Pay

Convertible Notes and Notes Payable	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes and Notes Payable	NOTE 8 – CONVERTIBLE NOTES AND NOTES PAYABLE At June 30, 2019, the Company is obligated for several convertible notes payable in the total amount of $280,000. The Company entered into these convertible notes during the quarter ended June 30, 2019. All of these convertible notes mature during the quarter ended June 30, 2021, two years from their inception dates. These convertible notes accrue interest at a rate of 10%. Accrued interest is due and payable each calendar quarter in cash; during the quarter ended June 30, 2019, the Company paid out $5,362 in accrued interest to these convertible note holders. These convertible notes automatically convert into shares of common stock at a rate of $.65 per share at the earlier of the maturity date or an uplift to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company’s stock price is at least $.78 at the time of the uplift. The convertible note holders have the right to convert their outstanding principal and interest into shares of the Company’s common stock at any time during their note’s term at $.65 per share. At June 30, 2019 the Company is obligated for one note payable and accrued interest in the total amount of $10,303. The note terms dictate 12% simple interest, compounding daily based on a 365-day year, paid out 6 months from the date of the note and the issuance of a detachable warrant for purchase of half of the principal amount in shares exercisable at $1.00 per share for a 3-year term. All debt discount associated with the warrants issued in conjunction with this note was charged to interest expense as of the maturity date of the note in February of 2019. Upon maturity of the note we entered into a note amendment whereby instead of paying out the entire outstanding balance of principal and interest, we were to pay an initial installment of $5,000 and then monthly payments of $3,000 until the amended maturity date of September 30, 2019.

Notes Payable - Related Party

Notes Payable - Related Party	3 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Notes Payable - Related Party	NOTE 9 – NOTES PAYABLE – RELATED PARTY At June 30, 2019 and March 31, 2019 the Company was obligated for a related party note payable and accrued interest in the total amount of $75,941 and $85,752, respectively; the maturity date of this note is April 30, 2020. The related party note payable terms are accrual of interest at 8% annually with payments of $3,100 per month, which are applied to interest first, then principal. The terms also include a stipulation that if the Company receives additional financing during any 24-month period from the date of the note in the amount greater than $3,500,000, the Company will immediately pay the officer the principal amount of the note along with all interest due.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES At June 30, 2019 and March 31, 2019, the Company is obligated to pay $849,668 and $854,990, respectively, in accounts payable and accrued expenses. Of the total at June 30, 2019 of $849,668, $523,377 is made up of accounts payable, while the $326,291 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. Of the total at March 31, 2019 of $854,990, $524,273 is made up of accounts payable, while the $330,717 in accrued expenses is made up of past employee’s accrued salaries and related payroll taxes payable. The Company has not paid the related payroll taxes, consisting primarily of Social Security and Medicare taxes. As a result, the Company has established an accrued liability for the unpaid salaries, along with related taxes of approximately $23,057 and $21,482 at June 30, 2019 and March 31, 2019, respectively.

Accrued Expenses - Related Part

Accrued Expenses - Related Party	3 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses - Related Party	NOTE 11 – ACCRUED EXPENSES – RELATED PARTY At June 30, 2019, the Company is obligated to pay $578,098 in accrued expenses due to related parties. Of the total, $76,918 is made up of accounts payable, while $501,180 is made up of accrued salaries and payroll taxes payable. At March 31, 2019, the Company was obligated to pay $576,393 in accrued expenses due to related parties. Of the total, $89,186 is made up of accounts payable, while $487,207 is made up of accrued salaries and payroll taxes payable.

Common Stock and Warrants

Common Stock and Warrants	3 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Common Stock and Warrants	NOTE 12 - COMMON STOCK AND WARRANTS Common Stock During the three-month period ended June 30, 2019 the Company did not issue any common stock. Warrants During the three-month period ended June 30, 2019, the Company granted warrants to purchase a total of 300,000 shares of common stock including: i) warrants for 300,000 shares, valued at $119,954 using the Black-Scholes model, to three new Directors, Messrs. Scott Johnson, Gregory Cash, and James Martin, with 150,000 vested immediately and 150,000 vesting quarterly between August 2020 and May 2021, and exercisable over a five-year term at $.30/share. A summary of warrant activity for the year ending March 31, 2019 and three-month period ending June 30, 2019 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2018 3,486,709 .59 2,433,601 .57 Granted 1,980,531 .41 Exercised 1,111,027 .36 Expired 12,977 .30 Canceled 100,000 1.00 Outstanding, March 31, 2019 4,243,236 .50 3,372,261 .49 Granted 300,000 .30 Cancelled 172,500 .54 Outstanding, June 30, 2019 4,370,736 .48 3,831,986 .47 At June 30, 2019, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Number of Weighted- Weighted- Number of Weighted- .30-.50 3,739,986 .35 4.36 3,391,236 .36 .51-1.00 517,500 1.00 3.39 327,500 1.00 1.01-3.50 113,250 2.35 2.08 113,250 2.35 Total 4,370,736 .48 4.19 3,831,986 .47 For the three-month periods ended June 30, 2019 and 2018, the total stock-based compensation on all instruments was $157,134 and $279,311, respectively. It is expected that the Company will recognize expense after June 30, 2019 related to warrants issued, outstanding, and valued using the Black Scholes pricing model as of June 30, 2019 in the amount of approximately $488,000.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 13 – INCOME TAXES The following table presents the net deferred tax assets as of June 30, 2019 and March 31, 2019: June 30, 2019 March 31, 2019 Net operating loss carryforwards: Federal $ (3,906,591 ) $ (3,801,404 ) State (1,823,076 ) (1,773,989 ) Total net operating loss carryforwards (5,729,666 ) (5,575,393 ) Total deferred tax assets (5,729,666 ) (5,575,393 ) Valuation allowance 5,729,666 5,575,393 Net deferred tax assets $ – $ – Current income taxes are based upon the year’s income taxable for federal and state tax reporting purposes. Deferred income taxes (benefits) are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. Deferred tax assets and liabilities are computed for differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the period in which the differences are expected to affect taxable income. The Company’s deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers would be limited under the Internal Revenue Code should a significant change in ownership occur within a three-year period. At June 30, 2019 and March 31, 2019, respectively, the Company had net operating loss carryforwards of approximately $18,600,000 and $18,100,000. The deferred tax assets arising from the net operating loss carryforwards are approximately $5,730,000 and $5,580,000 as of June 30, 2019 and March 31, 2019, respectively. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, the projected future taxable income and tax planning strategies in making this assessment. Based on management’s analysis, they concluded not to retain a deferred tax asset since it is uncertain whether the Company can utilize this asset in future periods. Therefore, they have established a full reserve against this asset. The net operating loss carryforwards, if not utilized, will begin to expire in 2021 for federal and Minnesota purposes. Of the approximately $18,600,000 in net operating loss carryforwards, approximately $7,000,000 has been accumulated in our pre-merger operating subsidiary, Gel-Del Technologies, Inc. IRC 382 provides guidance around whether or not the Company is able to utilize the pre-merger Gel-Del Technologies, Inc. net operating loss of approximately $7,000,000. Management is currently analyzing whether or not these pre-merger dollars will be allowable if our deferred tax asset is ever realized. A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total benefit for income taxes at June 30, 2019 and 2018 is as follows: 2019 2018 Expected tax at 21% and 9.8% $ (5,729,666 ) $ (5,477,233 ) Valuation allowance 5,729,666 5,477,233 Provision for income taxes $ – $ – The Company’s continuing practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2019 and 2018, the Company had no accrued interest and penalties related to uncertain tax positions. The Company is subject to taxation in the U.S. and Minnesota. Our tax years for 2016 and forward are subject to examination by tax authorities. The Company is not currently under examination by any tax authority. Management has evaluated tax positions in accordance with FASB ASC 740, and has not identified any tax positions, other than those discussed above, that require disclosure.

Loss Per Share

Loss Per Share	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Loss Per Share	NOTE 14 – LOSS PER SHARE At June 30, 2019, the Company had $280,000 in convertible notes outstanding that mature in our fiscal quarter ended June 30, 2021; see Note 8 to these financial statements for more information on these convertible notes. If converted, the $280,000 in outstanding convertible notes would convert into 430,769 shares of common stock at a rate of $.65 per share. At June 30, 2019 our if-converted weighted average number of shares outstanding was 22,347,532. Our if-converted loss per share remains consistent with our actual loss per share at ($.02).

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 – SUBSEQUENT EVENTS On July 31, 2019, the Company entered into an exclusive license agreement with Emerald Organic Products, Inc. (“Emerald”) whereby PetVivo granted an exclusive license to Emerald to use PetVivo’s proprietary Technology in the formulation, manufacture and sale of Emerald’s nutritional supplements including its hemp-based CBD wellness products. The Technology of PetVivo licensed to Emerald under the Agreement includes Patents and Know-how involved with protein-based active agent delivery systems and related carrier formulations for utilization in human nutritional supplement applications. The Company’s CEO and President, John Lai, owns approximately 3% of Emerald’s outstanding common stock. The Company’s Secretary, John Dolan, owns approximately 2% of Emerald’s outstanding common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	3 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of production, marketing and distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals, initially for dogs and horses. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at June 30, 2019 and for the three months ended June 30, 2019 and 2018 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended March 31, 2020 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2019, included in our annual report on Form 10-K filed with the SEC.
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. At June 30, 2019, the Company had $65,641 in cash and no cash equivalents. At March 31, 2019, the Company had $6,460 in cash and no cash equivalents.
Concentration-Risk	(F) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At June 30, 2019, cash did not exceed the FDIC uninsured balances and management believes the Company is not exposed to any significant credit risk on cash.
Property & Equipment	(G) Property & Equipment Property and equipment are recorded at cost less accumulated depreciation. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the asset’s estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(H) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of a useful life of 60 months or the life of the patent. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Loss Per Share	(I) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 4,370,736 warrants outstanding as of June 30, 2019 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.48/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company has 4,243,236 warrants outstanding as of March 31, 2019 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.50/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. The Company uses the guidance in ASC 260 to determine if-converted loss per share detailed in Note 14. ASC 260 states that convertible securities should be considered exercised at the later date of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be antidilutive.
Revenue Recognition	(J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements.
Research and Development	(K) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of investments – equity securities receivable, notes payable and accrued interest, notes payable and accrued interest - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2019 and March 31, 2019, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company measured its investments – equity securities receivable at fair value at June 30, 2019, see Note 5 to the financial statements included in this Form 10-Q. The Company had no assets and liabilities measured at fair value on a recurring basis at March 31, 2019.
Stock-Based Compensation - Non-employees	(M) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(N) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. As required by ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company applied ASC Topic 740 to all tax positions for which the statute of limitations remained open. As a result of the implementation of ASC Topic 740, the Company did not recognize any change in the liability for unrecognized tax benefits. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Inventory	(O) Inventory Inventories are recorded in accordance with ASC 330 and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (FIFO) methodology and capitalize costs on a project basis as they occur. The current marketed shelf life of our Kush inventory is 2 years. However, management reserves the right to review and adjust this as appropriate.
Recently Issued and Adopted Accounting Pronouncements	(P) Recently Issued and Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASU 2016-02 on April 1, 2019. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments (Subtopic 825) to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The amendments in this Update affect all entities that hold financial assets or owe financial liabilities. The amendments are meant to improve financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income since this Update requires equity securities to be measured at fair value with changes in the fair value recognized through net income. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted ASU 2016-01 on April 1, 2018. In August 2016, the FASB issued ASU No. 2016-15 Statement of Cashflows (Topic 230) to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments in this Update apply to all entities, including both business entities and not-for-profit entities that are required to present a statement of cash flows under Topic 230. This Update addresses eight specific cash flow issues and their presentations in the statement of cash flows. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2016-15 on April 1, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Total Inventory is broken out as follows: June 30, 2019 March 31, 2019 Finished Goods $ 67,310 $ 77,936 Reserve for Obsolete Inventory (67,310 ) (77,936 ) Work in Process -0- -0- Manufacturing Supplies 3,127 3,127 Raw Materials 9,368 9,368 Total Inventory $ 12,495 $ 12,495

Lease and Commitments (Tables)

Lease and Commitments (Tables)	3 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Maturity Analysis of Operating Lease Liabilities	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2019: Year Ended March 31, 2020 $ 18,702 2021 24,936 2022 24,936 2023 24,936 2024 10,390 $ 103,900
Schedule of Future Lease Payments	T he Company only had one operating lease so that the weighted average remaining lease term and weighted average discount rate are approximately 4.2 years and 2.18%, respectively. June 30, 2019 Present value of future base rent lease payments $ 101,269 Base rent payments included in prepaid expenses (2,070 ) Present value of future base rent lease payments – net 99,199
Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities	As of June 30, 2019, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: June 30, 2019 Operating lease right-of-use current asset $ - Operating lease right-of-use other asset 99,199 Total operating lease assets 99,199 Operating lease current liability 22,652 Operating lease other liability 76,547 Total operating lease liabilities $ 99,199

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Jun. 30, 2019
Property and Equipment:
Schedule of Property and Equipment	The components of property and equipment were as follows: June 30, 2019 March 31, 2019 Leasehold improvements $ 4,602 $ 4,602 Furniture and office equipment 10,130 10,130 Production equipment 108,882 108,882 R&D equipment 25,184 26,188 Total, at cost 148,798 149,802 Accumulated depreciation (118,430 ) (112,453 ) Total, net $ 30,368 $ 37,349

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The components of intangible assets, all of which are finite-lived, were as follows: June 30, 2019 March 31, 2019 Patents $ 3,838,865 $ 3,820,374 Trademarks 24,098 22,829 Total, at cost 3,862,963 3,843,203 Accumulated Amortization (3,390,495 ) (3,253,386 ) Total, net $ 472,468 $ 589,817

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	3 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the year ending March 31, 2019 and three-month period ending June 30, 2019 is as follows: Number of Weighted- Warrants Weighted- Outstanding, March 31, 2018 3,486,709 .59 2,433,601 .57 Granted 1,980,531 .41 Exercised 1,111,027 .36 Expired 12,977 .30 Canceled 100,000 1.00 Outstanding, March 31, 2019 4,243,236 .50 3,372,261 .49 Granted 300,000 .30 Cancelled 172,500 .54 Outstanding, June 30, 2019 4,370,736 .48 3,831,986 .47
Schedule of Range of Warrant Prices	At June 30, 2019, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Number of Weighted- Weighted- Number of Weighted- .30-.50 3,739,986 .35 4.36 3,391,236 .36 .51-1.00 517,500 1.00 3.39 327,500 1.00 1.01-3.50 113,250 2.35 2.08 113,250 2.35 Total 4,370,736 .48 4.19 3,831,986 .47

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	The following table presents the net deferred tax assets as of June 30, 2019 and March 31, 2019: June 30, 2019 March 31, 2019 Net operating loss carryforwards: Federal $ (3,906,591 ) $ (3,801,404 ) State (1,823,076 ) (1,773,989 ) Total net operating loss carryforwards (5,729,666 ) (5,575,393 ) Total deferred tax assets (5,729,666 ) (5,575,393 ) Valuation allowance 5,729,666 5,575,393 Net deferred tax assets $ – $ –
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total benefit for income taxes at June 30, 2019 and 2018 is as follows: 2019 2018 Expected tax at 21% and 9.8% $ (5,729,666 ) $ (5,477,233 ) Valuation allowance 5,729,666 5,477,233 Provision for income taxes $ – $ –

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Cash	$ 65,641	$ 6,460
Cash equivalents
Warrants outstanding	4,370,736	4,243,236
Assets and liabilities measured at fair value
Income tax likelihood percentage	Greater than 50 percent
Inventory terms	2 years
Warrant [Member] | Maximum [Member]
Warrant exercise price	$ 3.50	$ 3.50
Warrant [Member] | Minimum [Member]
Warrant exercise price	$ 0.30	$ 0.30
Patents And Trademarks [Member]
Estimated useful life of intangible asset	60 months
Equipment [Member]
Estimated useful life of assets	3 years
Automobiles [Member]
Estimated useful life of assets	5 years
Furniture and Fixtures [Member]
Estimated useful life of assets	7 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (500,887)	$ (2,099,585)
Net cash used in operating activities	(173,797)	$ (244,605)
Accumulated deficit	(53,006,799)		$ (52,505,912)
Working capital deficit	$ 1,408,592

Inventory (Details Narrative)

Inventory (Details Narrative)	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)
Inventory reserve	$ 67,000	$ 67,000
Inventory written down value		5,000
Inventory work-in-process	5,166	$ 5,166
Third - Party [Member]
Inventory written down value	$ 20,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Inventory Disclosure [Abstract]
Finished Goods	$ 67,310	$ 77,936
Reserve for Obsolete Inventory	(67,310)	(77,936)
Work in Process	0	0
Manufacturing Supplies	3,127	3,127
Raw Materials	9,368	9,368
Total Inventory	$ 12,495	$ 12,495

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	Jul. 13, 2018ft²	May 03, 2017USD ($)ft²	Jun. 30, 2019USD ($)Integer	Jun. 30, 2018USD ($)
Rent expense			$ 14,546	$ 14,607
Agreement term	1 year
Area of land | ft²	1,000
Base rent lease payments			103,900
Operating lease discounted value			$ 101,269
Operating lease discount rate			2.18%
Number of operating lease | Integer			1
Weighted average remaining lease term			4 years 2 months 12 days
Weighted average discount rate			2.18%
Amount payable to lessor			$ 103,900
Gel-Del Technologies, Inc [Member]
Amount payable to lessor			$ 330,000
Eighty-Four Month of Lease [Member]
Area of land | ft²		3,577
Monthly base rent		$ 2,078

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Maturity Analysis of Operating Lease Liabilities (Details)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 18,702
2021	24,936
2022	24,936
2023	24,936
2024	10,390
Total	$ 103,900

Lease and Commitments - Sched_2

Lease and Commitments - Schedule of Future Lease Payments (Details)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 101,269
Base rent payments included in prepaid expenses	(2,070)
Present value of future base rent lease payments - net	$ 99,199

Lease and Commitments - Sched_3

Lease and Commitments - Schedule of Present Value of Future Lease Payments Between Current and Non-current Assets and Liabilities (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use current asset
Operating lease right-of-use other asset	99,199
Total operating lease assets	99,199
Operating lease current liability	22,652
Operating lease other liability	76,547
Total operating lease liabilities	$ 99,199

Investments - Equity Securiti_2

Investments - Equity Securities (Details Narrative) - Purchase Agreement [Member] - Emerald Organic Products Inc [Member]	Jun. 28, 2019USD ($)shares
Number of shares purchased for acquisition | shares	1,500,000
Value of shares purchased for acquisition	$ 1,500
Fair value of investments	$ 1,500

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Property and Equipment:
Depreciation expense	$ 6,981	$ 1,652

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Total, at cost	$ 148,798	$ 149,802
Accumulated depreciation	(118,430)	(112,453)
Total, net	30,368	37,349
Leasehold Improvements [Member]
Total, at cost	4,602	4,602
Furniture and Office Equipment [Member]
Total, at cost	10,130	10,130
Production Equipment [Member]
Total, at cost	108,882	108,882
R&D Equipment [Member]
Total, at cost	$ 25,184	$ 26,188

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 137,109	$ 159,467

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,838,865	$ 3,820,374
Trademarks	24,098	22,829
Total, at cost	3,862,963	3,843,203
Accumulated Amortization	3,390,495	(3,253,386)
Total, net	$ 472,468	$ 589,817

Convertible Notes and Notes P_2

Convertible Notes and Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Convertible notes maturity date	Apr. 30, 2020
Convertible notes accrued interest rate		8.00%
Monthly installment payments	$ 3,100
Convertible Notes Payable [Member]
Convertible notes payable	$ 280,000
Convertible notes maturity date	Jun. 30, 2021
Convertible notes accrued interest rate	10.00%
Accrued interest	$ 5,362
Conversion price per share description	These convertible notes automatically convert into shares of common stock at a rate of $.65 per share at the earlier of the maturity date or an uplift to a national securities exchange (e.g. NASDAQ or New York Stock Exchange) provided that the Company's stock price is at least $.78 at the time of the uplift. The convertible note holders have the right to convert their outstanding principal and interest into shares of the Company's common stock at any time during their note's term at $.65 per share.
Conversion price per share	$ 0.65
Stock price	$ 0.78
One Note Payable [Member]
Convertible notes payable	$ 10,303
Convertible notes maturity date	Sep. 30, 2019
Debt simple interest percentage	12.00%
Debt maturity description	The note terms dictate 12% simple interest, compounding daily based on a 365-day year, paid out 6 months from the date of the note.
Warrants exercisable price per share	$ 1
Warrant term	3 years
Payment of initial installment	$ 5,000
Monthly installment payments	$ 3,000

Notes Payable - Related Party (

Notes Payable - Related Party (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Notes payable and accrued interest	$ 75,941	$ 85,752
Debt instrument maturity date	Apr. 30, 2020
Interest rate		8.00%
Annual monthly payments	$ 3,100
Debt term	24 months
Proceeds from related party debt
Minimum [Member]
Proceeds from related party debt	$ 3,500,000

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 849,668	$ 854,990
Accounts payable	523,377	524,273
Accrued salaries and related payroll taxes payable	326,291	330,717
Accrued liabilities	$ 23,057	$ 21,482

Accrued Expenses - Related Pa_2

Accrued Expenses - Related Party (Details Narrative) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Accrued expenses due to related parties	$ 578,098	$ 576,393
Accounts payable	523,377	524,273
Accrued salaries and payroll taxes payable	326,291	330,717
Related Party [Member]
Accrued expenses due to related parties	578,098	576,393
Accounts payable	76,918	89,186
Accrued salaries and payroll taxes payable	$ 501,180	$ 487,207

Common Stock and Warrants (Deta

Common Stock and Warrants (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Warrants to purchase shares of common stock	300,000	300,000	300,000
Warrant to purchase of common stock, value	$ 119,954	$ 119,954	$ 119,954
Stock-based compensation		157,134		$ 279,311
Expense related to warrants issued and outstanding		$ 488,000
August 2020 and May 2021 [Member]
Shares vested			150,000
Shares exercisable term			5 years
Shares exercisable price per share	$ 0.30	$ 0.30	$ 0.30
Scott Johnson [Member]
Shares vested	150,000
Gregory Cash [Member]
Shares vested	150,000
James Martin [Member]
Shares vested	150,000

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Number of Warrants, Outstanding, Beginning Balance	4,243,236	3,486,709
Number of Warrants, Granted	300,000	1,980,531
Number of Warrants, Exercised		1,111,027
Number of Warrants, Expired		12,977
Number of Warrants, Cancelled	172,500	100,000
Number of Warrants, Outstanding, Ending Balance	4,370,736	4,243,236
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$ 0.50	$ 0.59
Weighted-Average Exercise Price, Granted	0.30	0.41
Weighted-Average Exercise Price, Exercised		0.36
Weighted-Average Exercise Price, Expired		0.30
Weighted-Average Exercise Price, Cancelled	0.54	1
Weighted-Average Exercise Price, Outstanding, Ending Balance	$ 0.48	$ 0.50
Warrants Exercisable, Outstanding, Beginning Balance	3,372,261	2,433,601
Warrants Exercisable, Granted
Warrants Exercisable, Exercised
Warrants Exercisable, Expired
Warrants Exercisable, Cancelled
Warrants Exercisable, Outstanding, Ending Balance	3,831,986	3,372,261
Weighted-Average Exercisable Price, Outstanding, Beginning Balance	$ 0.49	$ 0.57
Weighted-Average Exercisable Price, Granted
Weighted-Average Exercisable Price, Exercised
Weighted-Average Exercisable Price, Expired
Weighted-Average Exercisable Price, Cancelled
Weighted-Average Exercisable Price, Outstanding, Ending Balance	$ 0.47	$ 0.49

Common Stock and Warrants - S_2

Common Stock and Warrants - Schedule of Range of Warrant Prices (Details) - Warrant [Member]	3 Months Ended
	Jun. 30, 2019$ / sharesshares
Number of Warrants, Outstanding | shares	4,370,736
Weighted-Average Exercise Price, outstanding	$ 0.48
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 2 months 8 days
Number of Warrants, Exercisable | shares	3,831,986
Weighted-Average Exercise Price, Exercisable	$ 0.47
Range One [Member]
Range of Warrant Exercise Price, Lower limit	0.30
Range of Warrant Exercise Price, Upper limit	$ 0.50
Number of Warrants, Outstanding | shares	3,739,986
Weighted-Average Exercise Price, outstanding	$ 0.35
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 4 months 9 days
Number of Warrants, Exercisable | shares	3,391,236
Weighted-Average Exercise Price, Exercisable	$ 0.36
Range Two [Member]
Range of Warrant Exercise Price, Lower limit	0.51
Range of Warrant Exercise Price, Upper limit	$ 1
Number of Warrants, Outstanding | shares	517,500
Weighted-Average Exercise Price, outstanding	$ 1
Weighted-Average Remaining Contractual Life (Years), Outstanding	3 years 4 months 20 days
Number of Warrants, Exercisable | shares	327,500
Weighted-Average Exercise Price, Exercisable	$ 1
Range Three [Member]
Range of Warrant Exercise Price, Lower limit	1.01
Range of Warrant Exercise Price, Upper limit	$ 3.50
Number of Warrants, Outstanding | shares	113,250
Weighted-Average Exercise Price, outstanding	$ 2.35
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 29 days
Number of Warrants, Exercisable | shares	113,250
Weighted-Average Exercise Price, Exercisable	$ 2.35

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Net operating loss carry forwards	$ 18,600,000	$ 18,100,000
Deferred tax assets operating loss carryforwards	$ 5,729,666	5,575,393
Net operating loss carry forwards, expiration period	The net operating loss carryforwards, if not utilized, will begin to expire in 2021 for federal and Minnesota purposes.
Accrued interest and penalties related to uncertain tax positions
Gel-Del Technologies, Inc [Member]
Net operating loss carry forwards	7,000,000
Accumulated pre-merger operting loss carryforwards	$ 7,000,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards: Federal	$ (3,906,591)	$ (3,801,404)
Net operating loss carryforwards: State	(1,823,076)	(1,773,989)
Total net operating loss carryforwards	(5,729,666)	(5,575,393)
Total deferred tax assets	(5,729,666)	(5,575,393)
Valuation allowance	5,729,666	5,575,393
Net deferred tax assets

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Expected tax at 21% and 9.8%	$ (5,729,666)	$ (5,477,233)
Change in valuation allowance	5,729,666	5,477,233
Provision for income taxes

Income Taxes - Schedule of Ef_2

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective tax rate, percentage	21.00%	9.80%

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Convertible notes maturity date	Apr. 30, 2020
Weighted average number of shares outstanding	22,074,667	19,584,396
Actual loss per share	$ (0.02)	$ (0.11)
Convertible Notes Payable [Member]
Convertible notes payable	$ 280,000
Convertible notes maturity date	Jun. 30, 2021
Number of shares converted into common stock	430,769
Value of shares converted into common stock	$ 280,000
Conversion price per share	$ 0.65
Weighted average number of shares outstanding	22,347,532
Actual loss per share	$ 0.02

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Jul. 31, 2019
John Lai [Member]
Equity ownership percentage	3.00%
John Dolan [Member]
Equity ownership percentage	2.00%